Easy-to-use software helps identify unknown compounds and extracts high-confidence understanding from complex mass spectra SAN DIEGO, June 4, 2018 /PRNewswire/ — ASMS 2018 – Scientists working in metabolomics, pharmaceuticals, food safety, and environmental and forensic science can now use a fully integrated software toolkit to transform complex, unknown mass spectra generated from small molecule analysis into actionable data.... Read more
MILFORD, Mass.–(BUSINESS WIRE)– Waters (NYSE:WAT) is giving scientists attending ASMS 2018 a first look at new mass spectrometry technologies developed to serve the multi-faceted analytical requirements of food testing, university and biomedical research laboratories. The new products include a gas chromatography-mass spectrometry/mass spectrometry (GC-MS/MS) system for food safety analyses and a direct-analysis mass spectrometry system... Read more
HAMBURG, Germany, June 4, 2018 /PRNewswire/ — Bruker today announced that it has acquired Sierra Sensors GmbH, based in Hamburg, Germany. Financial details were not disclosed. Sierra develops and manufactures innovative analytical biosensors based on Surface Plasmon Resonance (SPR) detection. Driven by patented technologies in the areas of SPR detection and microfluidic sample delivery, Sierra instruments... Read more
Cologne (DE) and Wageningen (NL) 04 June 2018 – Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of endotoxin products, services and software and provides pharmaceutical testing professionals with a comprehensive set of quality control (QC) tools. Under the agreement, Lonza... Read more
Mass Spectrometer System Offers Solution for Small Molecule Identification and Characterization New, easy-to-use analytical detection system extracts meaningful data quickly from acquisition to analysis SAN DIEGO, June 4, 2018 /PRNewswire/ — ASMS 2018 – Scientists can now use a powerful new system to automatically capture as much spectral information about small molecules as possible and efficiently... Read more
Basel, 02 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer Data will be featured in the ASCO press programme on Saturday 2 June and presented at ASCO on Monday 4 June Roche (SIX:... Read more
Basel, 02 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer Data will be featured in the ASCO press programme on Saturday 2 June and presented at ASCO on Monday 4 June Roche (SIX:... Read more
Basel, 01 June 2018 European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence An important new treatment option has been approved for patients in Europe with HER2-positive early breast cancer at high risk of recurrence in a setting where the goal of treatment is cure High... Read more
01 June, 2018 bioMérieux, a world leader in the field of industrial microbiological control, announces the launch of ENDOZYME® II GO, a new endotoxin test in the bioMérieux ENDONEXTTM range of recombinant horseshoe crab Factor C (rFC) assays. This new assay resulting from the combined expertise of bioMérieux in microbiology and Hyglos GmbH in endotoxin detection enables... Read more
Basel, 29 May 2018 Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival... Read more